Working… Menu
Trial record 1 of 1 for:    NCT03744676
Previous Study | Return to List | Next Study

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03744676
Recruitment Status : Recruiting
First Posted : November 16, 2018
Last Update Posted : February 18, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Juno Therapeutics, a Subsidiary of Celgene

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 30, 2023
Estimated Study Completion Date : October 30, 2023